Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dedee F Murrell

Showing results (221-230 of 258) with videos related to

Pageof 26
Sort By:
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
The Journal of Dermatology|March 20, 2025
Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnairesChika Tanemura, Maya Nunotani, Kyoko Kawabata, et al.
Veterinary Dermatology|August 18, 2020
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Stephen D White, Petra Bizikova, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled TrialJoyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
The British Journal of Dermatology|August 17, 2022
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradationMathilde C S C Vermeer, Mohammad Al-Shinnag, Herman H W Silljé, et al.
Trends in Cancer|March 13, 2025
Leveraging space innovations for cancer breakthroughs on EarthHossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, et al.
Cancer Research|May 9, 2012
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosaYi-Zhen Ng, Celine Pourreyron, Julio C Salas-Alanis, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Pageof 26

Showing results (221-230 of 258) with videos related to

Sort By:
Pageof 26
Journal of the American Academy of Dermatology|October 1, 2013
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosaSupriya S Venugopal, Wenfei Yan, John W Frew, et al.
The Journal of Dermatology|March 20, 2025
Development of Japanese versions of the Autoimmune Bullous Disease Quality of Life and Treatment of Autoimmune Bullous Disease Quality of Life questionnairesChika Tanemura, Maya Nunotani, Kyoko Kawabata, et al.
Veterinary Dermatology|August 18, 2020
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceusElizabeth C Goodale, Stephen D White, Petra Bizikova, et al.
BMC Cancer|April 20, 2019
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled TrialJoyce Teng, Amy S. Paller, Anna L. Bruckner, et al.
BMC Cancer|May 18, 2017
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC studyAleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin, et al.
The British Journal of Dermatology|August 17, 2022
A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradationMathilde C S C Vermeer, Mohammad Al-Shinnag, Herman H W Silljé, et al.
Trends in Cancer|March 13, 2025
Leveraging space innovations for cancer breakthroughs on EarthHossein Akbarialiabad, Parnian Jamshidi, Zahra Aminzade, et al.
Cancer Research|May 9, 2012
Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosaYi-Zhen Ng, Celine Pourreyron, Julio C Salas-Alanis, et al.
International Journal of Dermatology|January 13, 2010
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studiesPeter Foley, Michael Freeman, Alan Menter, et al.
Pageof 26